MRMatthew Brian Robers

Matthew Brian Robers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthew Brian Robers has a total of 199 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Denaturation-sensitive BRET probes enable intracellular thermal shift measurements across diverse protein targets and biomolecular complexes

    by James D. Vasta, Ani Michaud, Michael T. Beck, Inhong Hwang, Ashley Schwarzenstein, Cesear R. Corona, Paula Sequeira, Cara Happe, Martin P. Schwalm, Bryan Gehrke, et al.

    Thermal shift assays have revolutionized drug discovery, but can be limited in sensitivity and scalability. Combining the unique attributes of differential scanning fluorimetry (DSF) and cellular thermal shift (CETSA), we report the methodological framework for the bioluminescence resonance energy transfer shift assay (BRETSA). BRETSA utilizes denaturation sensitive BRET probes, in combination with luciferase-tagged target proteins, to track and longitudinally record thermal shift in living cells. Denaturation profiles were successfully measured for over 500 globular proteins, spanning 24 target families in diverse cellular compartments. Among these, target engagement was confirmed for over 200 proteins; including validated drug targets as well as understudied members of the kinase subfamily. Leveraging orthosteric, allosteric, and covalent ligands in potency studies, this method offers improved sensitivity and scalability compared to other thermal shift methods. We extend the utility of BRETSA to interrogate target engagement at biomolecular complexes and query cooperative binding for molecular glues and emerging tricomplex drug modalities.

  • Top Cited Papers

    Advances in BRET probes for intracellular target engagement studies

    by Jacob L. Capener, Martin P. Schwalm, James D. Vasta, Ani Michaud, Kelly A. Teske, William M. Marsiglia, Kilian V. M. Huber, Arvin C. Dar, Stefan Knapp, Alison D. Axtman, et al.

    Assessing drug-target engagement in living cells is essential for verifying the activity of pharmacological agents. Traditional binding assays often overlook key factors such as permeability, intracellular distribution and complex formation that influence target occupancy in cells. Bioluminescence resonance energy transfer (BRET)-based probes enable direct, quantitative assessment of small-molecule binding to proteins in live, intact cells. BRET provides sensitive detection of target engagement across a wide range of target classes, including less-tractable proteins in membrane compartments. Compared to other existing methods, BRET offers quantification of drug occupancy at steady state and open system regimens. Recent innovations in this platform have expanded its utility beyond occupancy confirmation to include applications in polypharmacology and mechanism-of-action studies. Here, we provide an updated perspective on BRET target engagement assays as versatile tools for chemical biology and early-stage drug discovery.


  • Open Access

    A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells

    by Elisabeth M. Rothweiler, Ani Michaud, Jakub Stefaniak, Usha Singh, Brynwood B. Mikulsky, James D. Vasta, Michael T. Beck, Jennifer Wilkinson, Jennifer A. Ward, Catherine M. Rogers, et al.

    Protein arginine methyl transferase 5 (PRMT5) plays a global role in cell physiology and is an established therapeutic target in cancer. In approximately 10-15% of human cancers, deletion of the methylthioadenosine phosphorylase (MTAP) gene results in accumulation of methylthioadenosine (MTA), exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate S-adenosyl methionine (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Although uncompetitive engagement can be evaluated in cell-free systems, no methods exist to directly assess this in cells. Here, we describe the development of a fluorescent probe that acts as a dynamic BRET biosensor of the intracellular SAM/MTA pool that overcomes the current limitations of competitive binding analyses. Using this biosensor, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement as well as ternary complex formation at PRMT5-SAM and PRMT5-MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent responses of inhibitors.


  • Open Access

    Cellular Context Influences Kinase Inhibitor Selectivity

    by Matthew J. Binder, Frances M. Bashore, Kaitlin K. Dunn Hoffman, Cameron Damgaard, Michael Slater, David H. Drewry, Matthew B. Robers, Alison D. Axtman

    A pivotal part of kinase chemical probe and drug development is assessment of the selectivity of a putative lead compound. While there is no consensus around the panel size or the type of assay(s) that are most appropriate, there is concurrence that gauging the number of on- and off-targets of a kinase inhibitor is essential. As pharmacology takes place in cells, we have compared profiling results for ten kinase inhibitors generated using the cell-free assays to those obtained when a panel of cellular target engagement NanoBRET assays is used to assess selectivity in intact cells. This is the first systematic comparison of these two approaches across a broad kinase panel. Comparison of the data sets demonstrates divergent results that can influence chemical probe prioritization. We identify unanticipated kinase interactions in cells for type II kinase inhibitors that are not observed in biochemical, cell-free systems. Furthermore, we characterize TPKI-39 as a DDR1, DDR2, and FLT1 chemical probe based on its in-cell selectivity profile. For Table of Contents Only:


  • Open Access

    A Live Cell BRET Probe to Quantify PRMT5-MTA Uncompetitive Target Engagement

    by Elisabeth Rothweiler, Ani Michaud, Jakub Stefaniak, Usha Singh, James Vasta, Michael Beck, Jennifer Ward, Catherine Rogers, Esra Balıkçı, Jeppe Tranberg-Jensen, et al.

    The PRMT5 methyltransferase plays a global role in cell physiology and is an established therapeutic target in cancer. In 10% of human cancers, deletion of the MTAP gene results in accumulation of MTA, exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Here we describe the development of a cell-permeable BRET probe CBH-002 that acts as a dynamic biosensor of the intracellular SAM/MTA pool. Using this probe, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement and ternary complex formation at PRMT5-SAM and -MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent response to inhibitors.

  • Thoughts for the future

    by Lona M. Alkhalaf, Cheryl Arrowsmith, Emily P. Balskus, Giovanna Bergamini, Rashna Bhandari, Christopher J. Chang, Peng Chen, Xing Chen, Alessio Ciulli, Julia A. Cricco, et al.


  • Open Access

    Small molecule engagement of kinase complexes in cells

    by Matthew Brian Robers

    Drug action is predicated on target engagement in cells and tissues. Historically, pure proteins or protein fragments have been used to query engagement and guide medicinal chemistry efforts toward optimized small molecule inhibitors. However, pure protein assays may fail to comprise the protein complexes and conformations relevant to the disease state. Thus, drug pharmacology observed in a defined, isolated setting may not correlate with pharmacology observed using a biomarker of target activity in the milieu of a living cell. Assessments of target vulnerability are ideally evaluated in live cells, in a microenvironment representing where drug action would occur. Kinases are among the most diverse classes of intracellular enzymes and are implicated in the pathophysiology of numerous diseases. With over 80 FDA approved kinase inhibitors, many kinases are intrinsically vulnerable to enzymatic inhibition via small molecule engagement in the ATP co-substrate binding pocket. Although such vulnerability is readily observed in an isolated setting, achieving selective intracellular engagement without collateral engagement to off-target kinases can be a major challenge. In cells, kinase engagement can be impacted by a number of factors, including ATP competition, multi-protein complexes, target activation state, and drug partitioning. Such factors can be difficult to simulate in a defined system, and methods to interrogate critical binding parameters in cells represents an unmet need. Therefore, intracellular engagement data and selectivity profiles for novel chemical matter is not generally reported in the literature, even for clinical-stage inhibitors. For many kinase inhibitors, cell- free data represents a vast over-estimate of the polypharmacology occurring in a native setting. Thus, providing a more physiologically-accurate assessment of compound selectivity and affinity would enable chemical probe initiatives and pharmaceutical discovery efforts. The RAS/RAF/MEK/ERK pathway (so called MAPK pathway) is among the most highly studied kinase-related pathways in human disease. These MAPK signaling components naturally function in a multi-protein complex (i.e., the RAS signalosome). Dysregulation in this pathway is known driver of tumorigenesis, and mutations in RAS or RAF are observed in >30% of human cancers. For example, RAF kinase is commonly mutated in melanoma, and the GTPase KRAS is the most mutated proto- oncogene in solid tumors. Despite ongoing multidisciplinary drug discovery efforts, this signaling complex has proven undruggable for several decades. As this multiprotein complex cannot currently be reconstituted in a biochemical setting, demonstrating vulnerability at protomers within the RAS/RAF complex has represented a significant challenge. Although potent drug binding or enzyme inhibition can be observed using isolated fragments of RAS or RAF kinase, the measured potencies are generally not commensurate with pathway inhibition in disease-relevant cells. For instance, despite sub-nM potency observed with clinical-stage RAF kinase inhibitors in enzymatic assays, potency of intracellular inhibition of MAPK signaling may be >100-1000-fold weaker. This opens the possibility that underappreciated drug escape mechanisms may be evident in cells that are not observed using purified components. Such observations cast doubt on the assumed mechanism of action of such clinical-stage drugs. Thus, new methods are needed to quantify drug engagement at these critical signaling components to support more accurate assessments of drug vulnerability. Herein are reported advancements in the Bioluminescence Resonance Energy Transfer (BRET) method to accurately query target engagement at monomeric and multiprotein complexes in cells. The prototype target engagement method leveraged an intracellular reporter system comprising NanoLuc (NLuc) tagged proteins in a BRET complex with cell-permeable fluorescent drug tracers. Engagement of unmodified compounds results in competitive displacement of the BRET complex in live cells. When the BRET tracers are applied at concentrations approximating their apparent affinity, the resulting IC50 of the test compound is within 2-fold of a constant value. Among all reported target engagement methods, BRET is the only method that offers quantitation in live cells. This quantitative accuracy allows for assessments of selectivity within target families. Furthermore, since the method operates with intact live cells, both affinity and binding kinetics can be measured. Using broad-spectrum BRET tracers, entire target families can be evaluated in a single experiment. Herein, a novel workflow is described, to enable improved broad-spectrum kinome profiling in live cells against nearly 200 full length protein kinases.

  • Open Access

    tracerDB: a crowdsourced fluorescent tracer database for target engagement analysis

    by Johannes Dopfer, James D. Vasta, Susanne Müller, Stefan Knapp, Matthew B. Robers, Martin P. Schwalm

    Investigating ligand-protein complexes is essential in the areas of chemical biology and drug discovery. However, detailed information on key reagents such as fluorescent tracers and associated data for the development of widely used bioluminescence resonance energy transfer (BRET) assays including NanoBRET, time-resolved Förster resonance energy transfer (TR-FRET) and fluorescence polarization (FP) assays are not easily accessible to the research community. We created tracerDB, a curated database of validated tracers. This resource provides an open access knowledge base and a unified system for tracer and assay validation. The database is freely available at https://www.tracerdb.org/.


  • Open Access

    Development of SYK NanoBRET Cellular Target Engagement Assays for Gain–of–Function Variants

    by Jacob L. Capener, James D. Vasta, Vittorio L. Katis, Ani Michaud, Michael T. Beck, Sabrina C. D. Daglish, Sarit Cohen-Kedar, Efrat Shaham Barda, Stefanie Howell, Iris Dotan, et al.

    Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase that is activated by phosphorylation events downstream of FcR, B-cell and T-cell receptors, integrins, and C-type lectin receptors. When the tandem Src homology 2 (SH2) domains of SYK bind to phosphorylated immunoreceptor tyrosine-based activation motifs (pITAMs) contained within these immunoreceptors, or when SYK is phosphorylated in interdomain regions A and B, SYK is activated. SYK gain-of-function (GoF) variants were previously identified in six patients that had higher levels of phosphorylated SYK and phosphorylated downstream proteins JNK and ERK. Furthermore, the increased SYK activation resulted in the clinical manifestation of immune dysregulation, organ inflammation, and a predisposition for lymphoma. The knowledge that the SYK GoF variants have enhanced activity was leveraged to develop a SYK NanoBRET cellular target engagement assay in intact live cells with constructs for the SYK GoF variants. Herein, we developed a potent SYK-targeted NanoBRET tracer using a SYK donated chemical probe, MRL-SYKi, that enabled a NanoBRET cellular target engagement assay for SYK GoF variants, SYK(S550Y), SYK(S550F), and SYK(P342T). We determined that ATP-competitive SYK inhibitors bind potently to these SYK variants in intact live cells. Additionally, we demonstrated that MRL-SYKi can effectively reduce the catalytic activity of SYK variants, and the phosphorylation levels of SYK(S550Y) in an epithelial cell line (SW480) stably expressing SYK(S550Y).

  • A Method to Conditionally Measure Target Engagement at Intracellular RAS and RAF Complexes

    by James D. Vasta, Ani Michaud, J. Aaron Crapster, Matthew B. Robers

    Dysfunction of the RAS/mitogen-activated protein kinase (MAPK) pathway is a common driver of human cancers. As such, both the master regulator of the pathway, RAS, and its proximal kinase effectors, RAFs, have been of interest as drug targets for decades. Importantly, signaling within the RAS/MAPK pathway is highly coordinated due to the formation of a higher-order complex called the RAS/RAF signalosome, which may minimally contain dimers of both RAS and RAF protomers. In the disease state, RAS and RAF assemble in homo- and/or heterodimeric forms. Traditionally, drug development campaigns for both RAS and RAF have utilized biochemical assays of purified recombinant protein. As these assays do not query the RAS or RAF proteins in their full-length and complexed forms in cells, potency results collected using these assays have often failed to correlate with inhibition of the MAPK pathway. To more accurately quantify engagement at this signaling components, we present a bioluminescence resonance energy transfer (BRET)-based method to conditionally measure target engagement at individual protomers within the RAS/RAF signalosome in live cells. Key words Target engagement Intracellular affinity BRET NanoBRET™ RAS RAF MAPK